With the improvement of survival of systemic lupus erythematosus (SLE) patients, prevention of organ damage has become a major goal in the management of these patients. The need for a reliable tool for assessment of cumulative damage over time led to the development of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index (SDI) that allowed a standardized measurement of damage and facilitated research in the field. Damage accumulates over the course of the disease; however, some patients do not accrue any damage even after many years. Damage accrues at a higher rate among patients with more active disease, highlighting the importance of prompt control of disease manifestations. However, medications administered to control disease activity, particularly corticosteroids, can also result in organ damage, emphasizing the need for adjustment of these agents as soon as disease is under control.
MerrellMShulmanLE. Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J Chronic Dis1955; 1: 12–32.
2.
HellerTAhmedMSiddiqqiAWallrauchCBahlasS. Systemic lupus erythematosus in Saudi Arabia: Morbidity and mortality in a multiethnic population. Lupus2007; 16: 908–914.
3.
DoriaAIaccarinoLGhirardelloA. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med2006; 119: 700–706.
4.
CerveraRKhamashtaMAFontJ. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore)2003; 82: 299–308.
5.
UrowitzMBGladmanDDTomBDIbañezDFarewellVT. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol2008; 35: 2152–2158.
6.
GladmanDGinzlerEGoldsmithC. Systemic lupus international collaborative clinics: Development of a damage index in systemic lupus erythematosus. J Rheumatol1992; 19: 1820–1821.
7.
GladmanDGinzlerEGoldsmithC. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum1996; 39: 363–369.
8.
GriffithsBMoscaMGordonC. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol2005; 19: 685–708.
9.
GladmanDDUrowitzMBGoldsmithCH. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum1997; 40: 809–813.
10.
BrunnerHIFeldmanBMUrowitzMBGladmanDD. Item weightings for the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Disease Damage Index using Rasch analysis do not lead to an important improvement. J Rheumatol2003; 30: 292–297.
11.
UrowitzMBGladmanDD. Measures of disease activity and damage in SLE. Baillieres Clin Rheumatol1998; 12: 405–413.
12.
GladmanDDUrowitzMB. The SLICC/ACR damage index: Progress report and experience in the field. Lupus1999; 8: 632–637.
13.
GladmanDDGoldsmithCHUrowitzMB. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol2000; 27: 373–376.
14.
GladmanDDUrowitzMBRahmanPIbañezDTamLS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol2003; 30: 1955–1959.
15.
StollTSeifertBIsenbergDA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol1996; 35: 248–254.
16.
UrowitzMBGladmanDDIbañezD. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken)2012; 64: 132–137.
17.
RahmanPGladmanDDUrowitzMBHallettDTamLS. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus2001; 10: 93–96.
18.
ChambersSAAllenERahmanAIsenbergD. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford)2009; 48: 673–675.
19.
AlarcónGSMcGwinGJrBartolucciAA. Systemic lupus erythematosus in three ethnic groups IX. Differences in damage accrual. Arthritis Rheum2001; 44: 2797–2806.
20.
UrowitzMBBookmanAAKoehlerBEGordonDASmytheHAOgryzloMA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med1976; 60: 221–225.
21.
SwaakAJvan den BrinkHGSmeenkRJ. Systemic lupus erythematosus: Clinical features in patients with a disease duration of over 10 years, first evaluation. Rheumatology (Oxford)1999; 38: 953–958.
22.
Zonana-NacachACamargo-CoronelAYáñezP. Measurement of damage in 210 Mexican patients with systemic lupus erythematosus: Relationship with disease duration. Lupus1998; 7: 119–123.
23.
BrunnerHISilvermanEDToTBombardierCFeldmanBM. Risk factors for damage in childhood-onset systemic lupus erythematosus: Cumulative disease activity and medication use predict disease damage. Arthritis Rheum2002; 46: 436–444.
24.
PineauCABernatskySAbrahamowiczMNevilleCKarpIClarkeAE. A comparison of damage accrual across different calendar periods in systemic lupus erythematosus patients. Lupus2006; 15: 590–594.
25.
FontJCerveraRNavarroM. Systemic lupus erythematosus in men: Clinical and immunological characteristics. Ann Rheum Dis1992; 51: 1050–1052.
MillerMHUrowitzMBGladmanDDKillingerDW. Systemic lupus erythematosus in males. Medicine (Baltimore)1983; 62: 327–334.
28.
MayorAMViláLM. Gender differences in a cohort of Puerto Ricans with systemic lupus erythematosus. Cell Mol Biol (Noisy-le-grand)2003; 49: 1339–1344.
29.
AzizahMRAinolSSKongNCNormaznahYRahimMN. Gender differences in the clinical and serological features of systemic lupus erythematosus in Malaysian patients. Med J Malaysia2001; 56: 302–307.
30.
HsuCYChiuWCYangTS. Age- and gender-related long-term renal outcome in patients with lupus nephritis. Lupus2011; 20: 1135–1141.
31.
Al-MayoufSMAl SonbulA. Influence of gender and age of onset on the outcome in children with systemic lupus erythematosus. Clin Rheumatol2008; 27: 1159–1162.
32.
MikdashiJHandwergerB. Predictors of neuropsychiatric damage in systemic lupus erythematosus: Data from the Maryland lupus cohort. Rheumatology (Oxford)2004; 43: 1555–1560.
33.
AndradeRMAlarcónGSFernándezM. Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort. Arthritis Rheum2007; 56: 622–630.
34.
AlarcónGSMcGwinGJrBastianHM. Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis Rheum2001; 45: 191–202.
35.
KarlsonEWDaltroyLHLewRA. The relationship of socioeconomic status, race, and modifiable risk factors to outcomes in patients with systemic lupus erythematosus. Arthritis Rheum1997; 40: 47–56.
36.
FernándezMCalvo-AlénJAlarcónGS. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women. Arthritis Rheum2005; 52: 1655–1664.
37.
WardMMStudenskiS. Clinical manifestations of systemic lupus erythematosus. Identification of racial and socioeconomic influences. Arch Intern Med1990; 150: 849–853.
38.
JohnsonAEGordonCPalmerRGBaconPA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum1995; 38: 551–558.
39.
ReveilleJDBartolucciAAlarcónGS. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum1990; 33: 37–48.
40.
WalshSJAlgertCGregorioDI. Divergent racial trends in mortality from systemic lupus erythematosus. J Rheumatol1995; 22: 1663–1668.
41.
TolozaSMRosemanJMAlarcónGS. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage. Arthritis Rheum2004; 50: 3177–3186.
42.
FernándezMAlarcónGSCalvo-AlénJ. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum2007; 57: 576–584.
43.
JohnsonSRUrowitzMBIbañezDGladmanDD. Ethnic variation in disease patterns and health outcomes in systemic lupus erythematosus. J Rheumatol2006; 33: 1990–1995.
44.
PeschkenCAEsdaileJM. Systemic lupus erythematosus in North American Indians: A population based study. J Rheumatol2000; 27: 1884–1891.
45.
PeschkenCAKatzSJSilvermanE. The 1000 Canadian faces of lupus: Determinants of disease outcome in a large multiethnic cohort. J Rheumatol2009; 36: 1200–1208.
46.
LopezRDavidsonJEBeebyMDEggerPJIsenbergDA. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology (Oxford)2012; 51: 491–498.
47.
BandeiraMBurattiSBartoliM. Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. Lupus2006; 15: 515–520.
48.
Ruiz-IrastorzaGEgurbideMVMartinez-BerriotxoaAUgaldeJAguirreC. Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus. Lupus2004; 13: 900–905.
49.
PrasadRIbañezDGladmanDUrowitzM. Anti-dsDNA and anti-Sm antibodies do not predict damage in systemic lupus erythematosus. Lupus2006; 15: 285–291.
50.
SteimanAJGladmanDDIbañezDUrowitz. Outcomes in patients with systemic lupus erythematosus (SLE) with and without a prolonged serologically active clinically quiescent (SACQ) period. Arthritis Care Res (Hoboken)2012; 64: 511–518.
51.
Zonana-NacachABarrSGMagderLSPetriM. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum2000; 43: 1801–1808.
52.
AlarcónGSRosemanJMMcGwinGJr. Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage. Rheumatology (Oxford)2004; 43: 202–205.
53.
StollTSutcliffeNKlaghoferRIsenbergDA. Do present damage and health perception in patients with systemic lupus erythematosus predict extent of future damage?: A prospective study. Ann Rheum Dis2000; 59: 832–835.
54.
GilboeIMKvienTKHusbyG. Disease course in systemic lupus erythematosus: Changes in health status, disease activity, and organ damage after 2 years. J Rheumatol2001; 28: 266–274.
55.
MangerKMangerBReppR. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis2002; 61: 1065–1070.
